Pressure BioSciences, Inc.
PBIO · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $2 | $1 |
| % Growth | 14.4% | -13.6% | 64% | – |
| Cost of Goods Sold | $1 | $2 | $1 | $1 |
| Gross Profit | $1 | -$0 | $1 | $1 |
| % Margin | 40.4% | -16.5% | 52.9% | 52.2% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $8 | $3 | $4 | $3 |
| SG&A Expenses | $9 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $1 | $0 | $0 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10 | $5 | $5 | $5 |
| Operating Income | -$10 | -$5 | -$4 | -$5 |
| % Margin | -480.5% | -283.2% | -209% | -375.7% |
| Other Income/Exp. Net | -$20 | -$11 | -$16 | -$11 |
| Pre-Tax Income | -$29 | -$16 | -$20 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$29 | -$16 | -$20 | -$16 |
| % Margin | -1,482.2% | -929.6% | -1,006.5% | -1,311.3% |
| EPS | -1.51 | -1.61 | -3.42 | -5.32 |
| % Growth | 6.2% | 52.9% | 35.7% | – |
| EPS Diluted | -1.51 | -1.61 | -3.42 | -5.32 |
| Weighted Avg Shares Out | 23 | 11 | 7 | 3 |
| Weighted Avg Shares Out Dil | 23 | 11 | 7 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $16 | $10 | $14 | $8 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$9 | -$5 | -$6 | -$7 |
| % Margin | -474.8% | -312.5% | -276.1% | -611% |